Targeted proteomics Leverage Proteome Sciences' expertise in SysQuant and TMT workflows to position advanced biomarker discovery and target identification services to pharma companies seeking novel disease markers and mechanism insights.

Clinical biomarker expansion Capitalize on capabilities in plasma proteomics via TMTcalibrator and Super-Depletion to offer high-sensitivity biomarker panels for diagnostic, prognostic, and treatment monitoring applications, targeting biotech firms and diagnostics developers.

Single cell edge Promote SysQuant SCP and single-cell proteomics capabilities to research labs and CROs aiming to deconvolute heterogeneity in tissue samples, creating opportunities for early engagement in drug discovery programs.

Capacity & investments Highlight recent financing and capital expansion, including plans for enabling equipment upgrades like Exploris mass spectrometers, as a signal to customers of growing throughput, reliability, and faster turnaround times.

Global reach Position Frankfurt ISO 9001:2015 and GCLP-certified operations as a quality-driven service backbone to attract pharmaceutical and diagnostics partners seeking compliant, globally transferable proteomics workflows.